High-risk acute pulmonary embolism affects around 5% of all pulmonary embolisms and can take a dramatic course even in young ...

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

A current study involving the University Hospital Bonn (UKB) has investigated which treatment strategy offers the best chances of survival in high-risk acute pulmonary embolism.

One study found that most people are at risk for developing DVT on one out of every 4,656 long flights, which is a relatively ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research ...

Learn about idiopathic pulmonary fibrosis, its symptoms, diagnosis, and treatment options for managing this lung disease.

Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC ...

Discover eight promising respiratory disease companies advancing their novel therapies through clinical trials in 2025.

ANSWER: Gabapentin was originally approved as a drug to control epilepsy, but it soon became clear that it was useful for chronic pain, especially the kind that comes from damaged nerves. But it can ...